MX2020012214A - Composiciones que comprenden moléculas que se unen a la pcsk9 y métodos de uso. - Google Patents
Composiciones que comprenden moléculas que se unen a la pcsk9 y métodos de uso.Info
- Publication number
- MX2020012214A MX2020012214A MX2020012214A MX2020012214A MX2020012214A MX 2020012214 A MX2020012214 A MX 2020012214A MX 2020012214 A MX2020012214 A MX 2020012214A MX 2020012214 A MX2020012214 A MX 2020012214A MX 2020012214 A MX2020012214 A MX 2020012214A
- Authority
- MX
- Mexico
- Prior art keywords
- pcsk9
- compositions
- methods
- binding molecules
- fibronectin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672187P | 2018-05-16 | 2018-05-16 | |
| PCT/US2019/032710 WO2019222529A1 (en) | 2018-05-16 | 2019-05-16 | Compositions comprising pcsk9-binding molecules and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012214A true MX2020012214A (es) | 2021-03-31 |
Family
ID=68540981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012214A MX2020012214A (es) | 2018-05-16 | 2019-05-16 | Composiciones que comprenden moléculas que se unen a la pcsk9 y métodos de uso. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10738102B2 (https=) |
| EP (1) | EP3793612A4 (https=) |
| JP (1) | JP7515406B2 (https=) |
| KR (1) | KR20210010890A (https=) |
| CN (2) | CN112423790B (https=) |
| AU (1) | AU2019269617B2 (https=) |
| BR (1) | BR112020023344A2 (https=) |
| CA (1) | CA3115341A1 (https=) |
| EA (1) | EA202092778A1 (https=) |
| IL (1) | IL278710B2 (https=) |
| MX (1) | MX2020012214A (https=) |
| SG (1) | SG11202011304QA (https=) |
| UA (1) | UA130399C2 (https=) |
| WO (1) | WO2019222529A1 (https=) |
| ZA (1) | ZA202007107B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3115341A1 (en) * | 2018-05-16 | 2019-11-21 | Lib Therapeutics, Llc | Compositions comprising pcsk9-binding molecules and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7932268B2 (en) * | 2004-03-05 | 2011-04-26 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
| US9994923B2 (en) * | 2008-04-23 | 2018-06-12 | Amgen Inc. | Neutralizing proprotein convertase subtilisin kexin type 9 (PCSK9) variants and uses thereof |
| EA022983B1 (ru) * | 2010-04-13 | 2016-04-29 | Бристол-Майерс Сквибб Компани | Белки на основе структурного домена фибронектина, связывающие pcsk9 |
| PL3395836T3 (pl) * | 2011-01-28 | 2021-12-13 | Sanofi Biotechnology | Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników |
| US9255154B2 (en) * | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US20160152686A1 (en) * | 2013-03-13 | 2016-06-02 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto |
| HK1213194A1 (zh) * | 2013-03-14 | 2016-06-30 | Daiichi Sankyo Co., Ltd. | 用於新型的结合蛋白质pcsk9 |
| EP3129401B1 (en) * | 2014-03-20 | 2019-06-12 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type iii domains |
| CN106795214B (zh) * | 2014-03-20 | 2022-09-02 | 百时美施贵宝公司 | 稳定化的基于纤连蛋白的支架分子 |
| EP3842451A1 (en) | 2015-03-12 | 2021-06-30 | MedImmune, LLC | Method of purifying albumin-fusion proteins |
| CA3115341A1 (en) * | 2018-05-16 | 2019-11-21 | Lib Therapeutics, Llc | Compositions comprising pcsk9-binding molecules and methods of use |
| CN117580583A (zh) * | 2021-06-25 | 2024-02-20 | 甘李药业股份有限公司 | Pcsk9抑制剂和glp-1受体激动剂的药物组合 |
-
2019
- 2019-05-16 CA CA3115341A patent/CA3115341A1/en active Pending
- 2019-05-16 UA UAA202008006A patent/UA130399C2/uk unknown
- 2019-05-16 IL IL278710A patent/IL278710B2/en unknown
- 2019-05-16 CN CN201980047552.9A patent/CN112423790B/zh active Active
- 2019-05-16 JP JP2020564676A patent/JP7515406B2/ja active Active
- 2019-05-16 AU AU2019269617A patent/AU2019269617B2/en active Active
- 2019-05-16 KR KR1020207035740A patent/KR20210010890A/ko not_active Ceased
- 2019-05-16 CN CN202510679381.9A patent/CN120643704A/zh active Pending
- 2019-05-16 SG SG11202011304QA patent/SG11202011304QA/en unknown
- 2019-05-16 EA EA202092778A patent/EA202092778A1/ru unknown
- 2019-05-16 WO PCT/US2019/032710 patent/WO2019222529A1/en not_active Ceased
- 2019-05-16 EP EP19804334.1A patent/EP3793612A4/en active Pending
- 2019-05-16 BR BR112020023344-7A patent/BR112020023344A2/pt unknown
- 2019-05-16 MX MX2020012214A patent/MX2020012214A/es unknown
- 2019-09-20 US US16/578,102 patent/US10738102B2/en active Active
-
2020
- 2020-07-21 US US16/934,816 patent/US11692021B2/en active Active
- 2020-11-13 ZA ZA2020/07107A patent/ZA202007107B/en unknown
-
2023
- 2023-05-16 US US18/318,343 patent/US12410236B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3793612A4 (en) | 2022-03-02 |
| IL278710A (https=) | 2021-01-31 |
| KR20210010890A (ko) | 2021-01-28 |
| EA202092778A1 (ru) | 2021-05-27 |
| WO2019222529A1 (en) | 2019-11-21 |
| US11692021B2 (en) | 2023-07-04 |
| US20230295270A1 (en) | 2023-09-21 |
| US10738102B2 (en) | 2020-08-11 |
| EP3793612A1 (en) | 2021-03-24 |
| IL278710B1 (en) | 2025-05-01 |
| AU2019269617A1 (en) | 2020-12-03 |
| AU2019269617A8 (en) | 2020-12-17 |
| IL278710B2 (en) | 2025-09-01 |
| ZA202007107B (en) | 2022-03-30 |
| CN120643704A (zh) | 2025-09-16 |
| CA3115341A1 (en) | 2019-11-21 |
| US20210002350A1 (en) | 2021-01-07 |
| BR112020023344A2 (pt) | 2021-02-09 |
| JP7515406B2 (ja) | 2024-07-12 |
| AU2019269617B2 (en) | 2026-01-08 |
| JP2021523214A (ja) | 2021-09-02 |
| UA130399C2 (uk) | 2026-02-11 |
| CN112423790B (zh) | 2025-05-16 |
| US12410236B2 (en) | 2025-09-09 |
| CN112423790A (zh) | 2021-02-26 |
| SG11202011304QA (en) | 2020-12-30 |
| US20200071386A1 (en) | 2020-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000704A1 (es) | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019) | |
| CO2019002239A2 (es) | Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados | |
| CL2019002542A1 (es) | Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap. | |
| MX391501B (es) | Agentes inductores de apoptosis | |
| CL2018002694A1 (es) | Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112) | |
| UY37554A (es) | (aza)indol- y benzofuran-3-sulfonamidas | |
| BR112017017286A2 (pt) | protease de cisteína | |
| BR112017017284A2 (pt) | protease de cisteína | |
| CL2022000087A1 (es) | Anticuerpo anti-tau y uso del mismo | |
| CO2019011265A2 (es) | Moduladores de la expresión de pcsk9 | |
| CR20190271A (es) | Anticuerpos antitau y métodos de uso | |
| UY37176A (es) | Apósitos modificados para heridas | |
| CL2018003132A1 (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas. | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| MX2016006226A (es) | Regimenes de dosificacion para uso con inhibidores de pcsk9. | |
| DOP2017000236A (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
| BR112019003816A2 (pt) | composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição | |
| UY37342A (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos | |
| CL2020000397A1 (es) | Formulaciones de anticuerpos inhibitorio para masp-2 de baja viscosidad altamente concentradas, kits, y métodos de tratamiento de sujetos que sufren de síndrome hemolítico atípico. | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| MX2020012214A (es) | Composiciones que comprenden moléculas que se unen a la pcsk9 y métodos de uso. | |
| SV2019005811A (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos | |
| CL2020002507A1 (es) | Variantes de lfa3 y composiciones y usos de las mismas | |
| BR112017022340A2 (pt) | 2-tiopirimidinonas | |
| BR112022009587A2 (pt) | Anticorpo anti-pcsk9 e uso do mesmo |